Trident Texofab [TTFL] vs Raymond [RAYMOND] Detailed Stock Comparison
Trident Texofab
BSE
Loading...
Raymond
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Trident Texofab wins in 3 metrics, Raymond wins in 14 metrics, with 0 ties. Raymond appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Trident Texofab | Raymond | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 103.29 | 97.25 | Raymond |
| Price-to-Book Ratio | 4.64 | 1.13 | Raymond |
| Debt-to-Equity Ratio | 62.67 | 17.81 | Raymond |
| PEG Ratio | N/A | 4.87 | N/A |
| EV/EBITDA | 44.92 | 16.00 | Raymond |
| Profit Margin (TTM) | 2.06% | 274.33% | Raymond |
| Operating Margin (TTM) | 2.47% | 8.79% | Raymond |
| EBITDA Margin (TTM) | 2.47% | 8.79% | Raymond |
| Return on Equity | 7.91% | 183.56% | Raymond |
| Return on Assets (TTM) | 2.62% | 98.90% | Raymond |
| Free Cash Flow (TTM) | $-137.08M | $752.80M | Raymond |
| 1-Year Return | 384.01% | -67.76% | Trident Texofab |
| Price-to-Sales Ratio (TTM) | 2.64 | 2.06 | Raymond |
| Enterprise Value | $2.46B | $49.13B | Raymond |
| EV/Revenue Ratio | 2.01 | 2.52 | Trident Texofab |
| Gross Profit Margin (TTM) | 14.02% | 27.67% | Raymond |
| Revenue per Share (TTM) | $116 | $0 | Trident Texofab |
| Earnings per Share (Diluted) | $2.08 | $6.50 | Raymond |
| Beta (Stock Volatility) | -1.45 | N/A | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Trident Texofab vs Raymond Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Trident Texofab | 0.73% | 0.35% | -0.39% | 12.43% | 30.09% | 25.24% |
| Raymond | -2.10% | -5.80% | -12.52% | -59.83% | -58.60% | -63.47% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Trident Texofab | 384.01% | 79.12% | 414.00% | 397.34% | 397.34% | 397.34% |
| Raymond | -67.76% | -33.91% | 131.17% | 36.18% | 65.16% | 67.17% |
Performance & Financial Health Analysis: Trident Texofab vs Raymond
| Metric | TTFL | RAYMOND |
|---|---|---|
| Market Information | ||
| Market Cap | ₹3.22B | ₹42.07B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 6,700 | 417,995 |
| 90 Day Avg. Volume | 18,958 | 2,574,168 |
| Last Close | ₹214.85 | ₹618.85 |
| 52 Week Range | ₹42.01 - ₹220.00 | ₹523.10 - ₹2,182.00 |
| % from 52W High | -2.34% | -71.64% |
| All-Time High | ₹220.00 (Jun 23, 2025) | ₹3,496.00 (Jul 08, 2024) |
| % from All-Time High | -2.34% | -82.30% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.27% | -0.41% |
| Quarterly Earnings Growth | 0.27% | -0.28% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 2.74% |
| Operating Margin (TTM) | 0.02% | 0.09% |
| Return on Equity (TTM) | 0.08% | 1.84% |
| Debt to Equity (MRQ) | 62.67 | 17.81 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹46.27 | ₹558.44 |
| Cash per Share (MRQ) | ₹3.09 | N/A |
| Operating Cash Flow (TTM) | ₹-137,076,992 | ₹-7,975,100,000 |
| Levered Free Cash Flow (TTM) | ₹-188,124,000 | ₹76.31B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | ₹0.00 | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Trident Texofab vs Raymond
| Metric | TTFL | RAYMOND |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 103.29 | 97.25 |
| Forward P/E | N/A | 4.87 |
| PEG Ratio | N/A | 4.87 |
| Price to Sales (TTM) | 2.64 | 2.06 |
| Price to Book (MRQ) | 4.64 | 1.13 |
| Market Capitalization | ||
| Market Capitalization | ₹3.22B | ₹42.07B |
| Enterprise Value | ₹2.46B | ₹49.13B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.01 | 2.52 |
| Enterprise to EBITDA | 44.92 | 16.00 |
| Risk & Other Metrics | ||
| Beta | -1.45 | N/A |
| Book Value per Share (MRQ) | ₹46.27 | ₹558.44 |
Financial Statements Comparison: Trident Texofab vs Raymond
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | TTFL | RAYMOND |
|---|---|---|
| Revenue/Sales | ₹382.06M | ₹-9.89B |
| Cost of Goods Sold | ₹328.49M | ₹-7.16B |
| Gross Profit | ₹53.58M | ₹-2.74B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹14.91M | ₹-2.04B |
| EBITDA | ₹18.34M | ₹-1.79B |
| Pre-Tax Income | ₹3.83M | ₹-1.81B |
| Income Tax | ₹-1.27M | ₹-976.70M |
| Net Income (Profit) | ₹5.10M | ₹1.37B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | TTFL | RAYMOND |
|---|---|---|
| Cash & Equivalents | ₹1.09M | ₹343.70M |
| Total Current Assets | ₹737.44M | ₹52.03B |
| Total Current Liabilities | ₹407.50M | ₹30.16B |
| Long-Term Debt | ₹102.71M | ₹3.45B |
| Total Shareholders Equity | ₹472.39M | ₹41.58B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹200.87M | ₹8.90B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | TTFL | RAYMOND |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | TTFL | RAYMOND |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 6,700 | 417,995 |
| Average Daily Volume (90 Day) | 18,958 | 2,574,168 |
| Shares Outstanding | 13.56M | 66.55M |
| Float Shares | 5.51M | 31.00M |
| % Held by Insiders | 0.38% | 0.52% |
| % Held by Institutions | 0.00% | 0.13% |
Dividend Analysis & Yield Comparison: Trident Texofab vs Raymond
| Metric | TTFL | RAYMOND |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹5.33 |
| 3-Year Avg Dividend Yield | N/A | 0.31% |
| 3-Year Total Dividends | ₹0.00 | ₹16.00 |
| Ex-Dividend Date | N/A | Jun 13, 2024 |